Cleerly Company Profile

Cleerly is a comprehensive, AI-driven platform that quantifies and assesses coronary artery disease (CAD) to deliver clinically actionable insights through a web-based solution. Cleerly's software quantifies atherosclerosis by measuring plaque volume, composition, length, and location, evaluates stenosis severity in both 2D (diameter and area) and 3D (lumen and vessel volume), with a workflow for determining the likely presence or absence of ischemia. James K. Min, MD, Founder and CEO of Cleerly, leads the company, which is remote-first with teams across the United States and in Portugal.

Cleerly's approach is grounded in science, based on millions of images from over 40,000 patients, and Coronary Artery Disease (CAD) accounts for more than 900k fatalities a year. Several Medicare Administrative Contractors (MACs) have officially approved Artificial Intelligence-enabled Quantitative Coronary Tomography (AI-QCT) scans for Medicare recipients with stable and acute symptoms suspicious of coronary artery disease.

Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds Cleerly.

Often trade at a premium or discount to NAV.

Platforms match existing holders with buyers. Cleerly availability at any moment is set by the holders.

High minimums, transfer approval, company right-of-first-refusal.

Valuations, rounds and IPO status for every company in the directory — Cleerly included.

The routes section explains what is realistically available for a company at this stage.

No. Cleerly is a private company; its shares do not trade on a public exchange.

Lead investors for each round are in the funding timeline.

The closest fintech/wealth peers are on the competitors page.